Additionally, c‐Kit‐targeting ADCs can treat cancer cells overexpressing wild‐type or mutant c‐Kit even if the SCF/c‐Kit pathway is not the major pathway mediating the pathogenesis of cancer (as observed in SCLC). This evidence concerns the gene KITLG and small cell lung carcinoma.